HMGB1 and neoplasm: Phase I trial (NCT01811992) of adenovirus mediated delivery of FMS like tyrosine kinase 3 ligand (Flt3L, which stimulates the migration of dendritic cells) along with Ad tyrosine kinase and ganciclovir increased survival of mice, and generated tumor-specific T-cell responses and long-term cell memory, along with release of HMGB1 by dying tumor cells [265].